Evidence map›Paper›PMID 35677044›Full record

Trial reportFrontiers in immunology2022

Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three Countries.

Pauline Versteegen, Alex-Mikael Barkoff, Marta Valente Pinto, Jan van de Kasteele, Aapo Knuutila, Sagida Bibi, Lia de Rond, Johanna Teräsjärvi, Katherine Sanders, Mary-Lène de Zeeuw-Brouwer and 10 more

Open access · goldAbstract readClinical Trial, Phase IVMulticenter Study
In one paragraph

Trial report in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 3 countries.

Pauline VersteegenNational Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.
Alex-Mikael BarkoffInstitute of Biomedicine, Microbiology, Virology and Immunology, and Turku University Hospital, University of Turku, Turku, Finland.
Marta Valente PintoDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.
Jan van de KasteeleNational Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.
Aapo KnuutilaInstitute of Biomedicine, Microbiology, Virology and Immunology, and Turku University Hospital, University of Turku, Turku, Finland.
Sagida BibiDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.
Lia de RondNational Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.
Johanna TeräsjärviInstitute of Biomedicine, Microbiology, Virology and Immunology, and Turku University Hospital, University of Turku, Turku, Finland.
Katherine SandersDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.
Mary-Lène de Zeeuw-BrouwerNational Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.
Raakel LuotoInstitute of Biomedicine, Microbiology, Virology and Immunology, and Turku University Hospital, University of Turku, Turku, Finland.
Hinke Ten HulscherNational Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.
Elizabeth A ClutterbuckDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.
Elisabeth A M SandersNational Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.
Jussi MertsolaInstitute of Biomedicine, Microbiology, Virology and Immunology, and Turku University Hospital, University of Turku, Turku, Finland.
Guy A M BerbersNational Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.
Qiushui HeInstitute of Biomedicine, Microbiology, Virology and Immunology, and Turku University Hospital, University of Turku, Turku, Finland.
Dominic F KellyDepartment of Paediatrics, Oxford Vaccine Group, University of Oxford, Oxford, United Kingdom.
Anne-Marie BuismanNational Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands.
PERISCOPE Consortium
National Institute for Public Health and the Environment · NLUniversity of Turku · FIUniversity of Oxford · GBOxford BioMedica (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immunogenicity of acellular pertussis (aP) vaccines is conventionally assessed by measuring antibody responses but antibody concentrations wane quickly after vaccination. Memory B cells, however, are critical in sustaining long-term protection and therefore may be an important factor when assessing pertussis immunity after vaccination. Aim: We studied pertussis specific memory B cell (re)activation induced by an aP booster vaccination in four different age groups within three countries. Materials and methods: From a phase IV longitudinal interventional study, 268 participants across Finland, the Netherlands and the United Kingdom were included and received a 3-component pertussis booster vaccine: children (7-10y, n=53), adolescents (11-15y, n=66), young adults (20-34y, n=74), and older adults (60-70y, n=75). Memory B cells at baseline, day 28, and 1 year post-vaccination were measured by a pertussis toxin (Ptx), filamentous haemagglutinin (FHA), and pertactin (Prn) specific ELISpot assay. Antibody results measured previously were available for comparison. Furthermore, study participants were distributed into groups based on their baseline memory B cell frequencies, vaccine responses were monitored between these groups. Results: Geometric mean (GM) memory B cell frequencies for pertussis antigens at baseline were low. At 28 days post-vaccination, these frequencies increased within each age group and were still elevated one year post-booster compared to baseline. Highest frequencies at day 28 were found within adolescents (GM: 5, 21, and 13, for Ptx, FHA and Prn, respectively) and lowest within older adults (GM: 2, 9, and 3, respectively). Moderate to strong correlations between memory B cell frequencies at day 28 and antibody concentrations at day 28 and 1 year were observed for Prn. Memory B cell frequencies > 1 per 100,000 PBMCs at baseline were associated with significantly higher memory responses after 28 days and 1 year. Conclusions: An aP booster vaccine (re)activated memory B cells in all age groups. Still elevated memory B cell frequencies after one year indicates enhanced immunological memory. However, antigen specific memory B cell activation seems weaker in older adults, which might reflect immunosenescence. Furthermore, the presence of circulating memory B cells at baseline positively affects memory B cell responses. This study was registered at www.clinicaltrialsregister.eu: No. 2016-003678-42.

Indexed as

Memory B CellsPertussis VaccineAdolescentAdultAgedChildHumansMiddle AgedPertussis ToxinVaccinationWhooping CoughYoung AdultPertussis ToxinPertussis Vaccineadolescentsadultschildrenlongitudinalmemory B cellsolder adultspertussisvaccination

Identifiers

PMID35677044
PMCPMC9168128
OpenAlexW4281293568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.